Register
FDA approves Revcovi for adenosine deaminase severe combined immune deficiency |
Journal Updates
eMediNexus Coverage from: 
FDA approves Revcovi for adenosine deaminase severe combined immune deficiency
eMediNexus,  10 October 2018
remove_red_eye 449 Views
#Pathology and Lab Medicine #Pharmacist

0 Read Comments                

The US Food and Drug Administration (FDA) has approved elapegademase-lvlr (Revcovi, Leadiant Biosciences) for the treatment of adults and children with adenosine deaminase severe combined immune deficiency.


Comments

Comments on eMediNexus are moderated. We retain the right to remove any comments at our sole discretion.